Moraga, Calif. March 9, 2016—Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of targeted neurological drug therapies, announced today that the company will present at the BIO Asia 2016 International Conference, which will be held in Tokyo, Japan next week. The presentation will be made by Charles Yeomans, president and chief executive officer of Trigemina, and will occur on Wednesday, March 16, at 2:15p.m. JST.
“We look forward to presenting at BIO Asia this year and to the slate of partnering meetings that we have arranged during the conference,” stated Mr. Yeomans. “The transition from Phase 2a to a dose ranging clinical trial planned for later this year, combined with the closing of a $7.5 million financing in 2015, has given us momentum to continue to advance our lead product candidate, TI-001, for the treatment of migraine headaches through development.”
About BIO Asia 2016 International Conference
The BIO Asia International Conference, co-hosted by the Biotechnology Innovation Organization (BIO), BioCentury and the Japan Bioindustry Association (JBA), brings together the global biotechnology and pharmaceutical industry to explore licensing and research collaborations in the current Asia-Pacific business and policy environments.
Trigemina is developing easy-to-use, highly-targeted, nose-to-brain therapies for patients with debilitating CNS disorders. Our platform is based on proprietary formulations of oxytocin, a naturally-occurring hormone, delivered through nasal-cerebral pathways for the treatment of a large spectrum of chronic and acute neurological disorders with high unmet medical need. Our lead product, a site-specific blocker of CGRP release in the CNS, is in late-stage development for the prevention of high frequency episodic and chronic migraine in both adults and adolescents. www.trigemina.com
President and CEO, Trigemina
Cook Williams Communications, Inc.